[go: up one dir, main page]

WO2003034977A3 - Combination therapy for treating disease - Google Patents

Combination therapy for treating disease Download PDF

Info

Publication number
WO2003034977A3
WO2003034977A3 PCT/IB2002/005794 IB0205794W WO03034977A3 WO 2003034977 A3 WO2003034977 A3 WO 2003034977A3 IB 0205794 W IB0205794 W IB 0205794W WO 03034977 A3 WO03034977 A3 WO 03034977A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
immune response
binding agent
host immune
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/005794
Other languages
French (fr)
Other versions
WO2003034977A2 (en
Inventor
Birgit C Schultes
Christopher F Nicodemus
Antoine Noujaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Priority to CA2464947A priority Critical patent/CA2464947C/en
Priority to AT0923902A priority patent/AT500649A1/en
Priority to DE10297379T priority patent/DE10297379T5/en
Priority to GB0409191A priority patent/GB2397018B/en
Priority to AU2002358246A priority patent/AU2002358246B2/en
Publication of WO2003034977A2 publication Critical patent/WO2003034977A2/en
Priority to US10/831,886 priority patent/US8038994B2/en
Anticipated expiration legal-status Critical
Priority to NO20042166A priority patent/NO20042166L/en
Publication of WO2003034977A3 publication Critical patent/WO2003034977A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methods for treating cancer comprising administering a xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen in present in the host serum, which antigen does not elicit a host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
PCT/IB2002/005794 1996-05-15 2002-10-28 Combination therapy for treating disease Ceased WO2003034977A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2464947A CA2464947C (en) 2001-10-26 2002-10-28 Combination therapy for treating disease
AT0923902A AT500649A1 (en) 2001-10-26 2002-10-28 COMBINATION THERAPY FOR DISEASE TREATMENT
DE10297379T DE10297379T5 (en) 2001-10-26 2002-10-28 Combination therapy for disease treatment
GB0409191A GB2397018B (en) 2001-10-26 2002-10-28 Combination therapy for treating disease
AU2002358246A AU2002358246B2 (en) 2001-10-26 2002-10-28 Combination therapy for treating disease
US10/831,886 US8038994B2 (en) 1996-05-15 2004-04-26 Combination therapy for treating disease
NO20042166A NO20042166L (en) 2001-10-26 2004-05-25 Combination therapy for the treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33924001P 2001-10-26 2001-10-26
US60/339,240 2001-10-26

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB1996/000461 Continuation-In-Part WO1997042973A1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US08913290 Continuation-In-Part 1996-05-15
US10/831,886 Continuation-In-Part US8038994B2 (en) 1996-05-15 2004-04-26 Combination therapy for treating disease

Publications (2)

Publication Number Publication Date
WO2003034977A2 WO2003034977A2 (en) 2003-05-01
WO2003034977A3 true WO2003034977A3 (en) 2004-05-27

Family

ID=23328122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005794 Ceased WO2003034977A2 (en) 1996-05-15 2002-10-28 Combination therapy for treating disease

Country Status (9)

Country Link
AT (1) AT500649A1 (en)
AU (1) AU2002358246B2 (en)
CA (1) CA2464947C (en)
CH (1) CH696871A5 (en)
DE (1) DE10297379T5 (en)
ES (1) ES2304264A1 (en)
GB (1) GB2397018B (en)
NO (1) NO20042166L (en)
WO (1) WO2003034977A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2008091643A2 (en) * 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012217A1 (en) * 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2144522T3 (en) * 1993-05-27 2000-06-16 Uwe Dr Med Wagner ANTI-CA125 ANTIBODIES MONOCLONAL ANTI-IDIOTIPIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PT910407E (en) * 1996-05-15 2003-07-31 Altarex Inc METHOD AND COMPOSITION FOR MODIFYING THE CONFORMATION OF MULTI-EPITHOPIC ANTIGENS IN ORDER TO START AN IMMUNE RESPONSE
CH694589A5 (en) * 1999-06-25 2005-04-15 Genentech Inc Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies.
AU5286999A (en) * 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
PL202369B1 (en) * 1999-08-27 2009-06-30 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI−ErbB2 ANTIBODIES
EP1254374B1 (en) * 2000-02-08 2007-04-18 AltaRex Medical Corporation Method for diagnosing efficacy of xenotypic antibody therapy
GB2390811B (en) * 2001-03-21 2006-01-18 Altarex Inc Therapeutic compositions that alter the immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012217A1 (en) * 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLD D.V. ET AL.: "Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin", INT. J. CANCER, vol. 57, 1994, pages 204 - 210, XP002963400 *
NG B. ET AL.: "Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts", CANCER RESEARCH, vol. 61, 1 April 2001 (2001-04-01), pages 2996 - 3001, XP002963364 *

Also Published As

Publication number Publication date
GB2397018B (en) 2006-05-31
NO20042166L (en) 2004-05-25
CH696871A5 (en) 2008-01-15
ES2304264A1 (en) 2008-10-01
AT500649A1 (en) 2006-02-15
DE10297379T5 (en) 2004-10-14
WO2003034977A2 (en) 2003-05-01
GB0409191D0 (en) 2004-05-26
GB2397018A (en) 2004-07-14
AU2002358246B2 (en) 2008-02-28
CA2464947C (en) 2012-05-22
CA2464947A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
IL126803A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2005035584A8 (en) Fully human antibodies against human 4-1bb (cd137)
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
HUP0303173A2 (en) Modified anti-egfr antibodies with reduced immunogenicity
WO2002100326A3 (en) Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2004032857A8 (en) Antibody therapy
RU2008128244A (en) METHODS FOR IDENTIFICATION OF TUMORS SUSCEPTIBLE TO TREATMENT BY ANTIBODIES AGAINST ERBB2
WO2001005425A3 (en) Combined preparations comprising daunorubicin derivatives and her2 antibodies
IL192679A0 (en) Aglyco products and uses thereof
JP2003519096A5 (en)
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2006130773A3 (en) Methods of treating brain tumors with antibodies
WO2005055936A3 (en) Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
WO2003034977A3 (en) Combination therapy for treating disease
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2001036485A3 (en) Recombinant monoclonal antibodies recognizing antigen ior c2 and the use thereof in the diagnosis and treatment of colorectal tumors
WO2005042028A3 (en) Il-13 conjugated to an immunogen and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 0409191

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20021028

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002358246

Country of ref document: AU

Ref document number: 2464947

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 200450028

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200450028

Country of ref document: ES

WWE Wipo information: entry into national phase

Ref document number: A9239/2002

Country of ref document: AT

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 200450028

Country of ref document: ES

Kind code of ref document: A

WWR Wipo information: refused in national office

Ref document number: 200450028

Country of ref document: ES

Kind code of ref document: A